ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).
The company is based in the premises of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team.
ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique discovery platform for the identification of intracellular therapeutic targets and first-in-class molecules.
The company is currently developing treatments against liver diseases. Other therapeutic areas are also investigated through ongoing development programs. ENYO Pharma owns an exhaustive database of all known virus-human protein protein interactions from which new cellular targets are discovered. From that, small active molecules are designed and developed. The company plans to conduct its molecules to Phase II clinical trials.